Not Signed In - Genzyme Reports Interim Results From Trial Of Campath(R) For Multiple Sclerosis
Fri, 15 Sep 2006 07:00 AM EST
... Genzyme Corporation (Nasdaq: GENZ) today announced two-year interim results from a Phase 2 trial comparing Campath(R) (alemtuzumab) with Rebif(R) (interferon beta-1a) for the treatment of multiple sclerosis. The results derive from a pre-specified analysis conducted after two years of treatment for 334 patients in the planned three-year trial. [click link for full article] ...
Related Topics
- Clinical Trials
- Multiple Sclerosis/ms
- Multiple Sclerosis
- Alemtuzumab
- Tuberous Sclerosis
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Lichen Sclerosis
- Multiple Chemical Sensitivity
- Interferon Beta-1a Injection (Rebif
- Interferon Beta-1a Injection (Avonex
- Twins, Triplets, Multiple Births
- Multiple System Atrophy
- Recessive multiple epiphyseal dysplasia
- Naltrexone
- Hypothermia
- Aspartame
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Cerebral Atrophy
email this page
print this page
bookmark this page
feedback on this page
